Despite early detection and reduced risk of death, prostate cancer still remains the second leading cause of cancer death in American men. There is currently no cure for advanced prostate cancer. The multistage, stochastic and highly heterogeneous nature of prostate cancer, coupled with genetic and epigenetic alterations that occur during disease progression and response to therapy, represent fundamental challenges in our quest to understand and control this complex and prevalent disease. Recent advances in drug development and breakthroughs in omics technologies have renewed our efforts to identify novel biomarkers for prostate cancer prognosis, prediction, and therapeutic response monitoring. In this perspective article, we overview the current status and highlight future prospects of biomarkers for prostate cancer, a disease that affects millions of men worldwide.
Written by:
Liu Y, Hegde P, Zhang F, Hampton G, Jia S Are you the author?
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA
Reference: Front Endocrinol (Lausanne). 2012;3:72
doi: 10.3389/fendo.2012.00072
PubMed Abstract
PMID: 22661971